Collegium Pharmaceutical, Inc. (COLL)

Market Cap	1.18B
Revenue (ttm)	707.01M
Net Income (ttm)	36.27M
Shares Out	31.50M
EPS (ttm)	1.06
PE Ratio	35.26
Forward PE	4.83
Dividend	n/a
Ex-Dividend Date	n/a

Volume	412,913
Open	38.40
Previous Close	39.06
Day's Range	37.27 - 38.49
52-Week Range	23.23 - 42.29
Beta	0.63
Analysts	Strong Buy
Price Target	44.25 (+18.54%)
Earnings Date	Nov 6, 2025

About COLL

Collegium Pharmaceutical, Inc., a specialty pharmaceutical company, engages in the development and commercialization of medicines for pain management. The company’s portfolio includes Jornay PM, a central nervous system stimulant prescription medicine that contains methylphenidate HCl for the treatment of attention deficit hyperactivity disorder; Belbuca, a buccal film that contains buprenorphine for severe and persistent pain that requires an extended treatment period; Xtampza ER, an abuse-deterrent, extended-release, oral formulation of oxyco...

• Industry: Drug Manufacturers - Specialty & Generic
• Sector: Healthcare
• IPO Date: May 7, 2015
• Employees: 357
• Stock Exchange: NASDAQ
• Ticker Symbol: COLL
• Website: https://www.collegiumpharma.com

Financial Performance

In 2024, Collegium Pharmaceutical's revenue was $631.45 million, an increase of 11.41% compared to the previous year's $566.77 million. Earnings were $69.19 million, an increase of 43.68%.

Analyst Summary

According to 4 analysts, the average rating for COLL stock is "Strong Buy." The 12-month stock price target is $44.25, which is an increase of 18.54% from the latest price.

Price Target

$44.25

(18.54% upside)

Analyst Consensus: Strong Buy